Welcome to our dedicated page for GE HealthCare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on GE HealthCare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
GE HealthCare has announced the launch of Pixxoscan (gadobutrol), a new Magnetic Resonance Imaging (MRI) contrast agent, expanding its portfolio alongside Clariscan (gadoteric acid). Pixxoscan shares the same active substance and formulation as the reference product, Gadovist, and is aimed at enhancing the accessibility of MRI procedures for radiology departments. Market authorization is already in place in Austria, with additional approvals expected in several European countries throughout 2023. Pixxoscan is indicated for various MRI applications, offering high relaxivity for improved visualization of tissues and abnormalities. The product will be available in multiple packaging options, enhancing convenience and reducing environmental impact.
GE HealthCare has launched the next-generation bkActiv system, expanding its application into Urology, Colorectal, and Pelvic Floor surgeries. This advanced intraoperative ultrasound imaging system is designed to enhance surgeons' ability to visualize anatomical structures, offering exceptional control during procedures. Key features include automatic no-touch autogain and advanced algorithms for superior image quality, enabling confident, real-time surgical decision-making with minimal user interaction. The bkActiv’s new advancements include detailed imaging capabilities for prostate, kidney, and bladder surgeries, as well as sophisticated color Doppler technology. This launch is part of GE HealthCare's strategy to leverage its acquisition of BK Medical and expand its ultrasound offerings.
GE HealthCare reported a strong financial performance for Q1 2023, with revenues of $4.7 billion, an 8% increase year-over-year. Organic revenue growth reached 12%, significantly aided by improved supply chain fulfillment. Net income attributable to the company was $372 million, a decline from $389 million in Q1 2022. Diluted EPS fell to $0.41 from $0.86 in the previous year, primarily due to a noncontrolling interest redemption. However, Adjusted EBIT rose to $664 million, reflecting an increase in operational efficiency, while cash flow from operations remained steady at $468 million.
The board declared a dividend of $0.03 per share, and the company maintains its organic revenue growth guidance for 2023 between 5% to 7%.